Contrasting with our results, elevated H-FABP levels measured within 12–24 h after ACS symptom onset in the literature are associated with a significantly increased risk of all-cause and CV mortality (4.1-fold higher HR), recurrent MI (HR 1.6), and developing HF (HR 4.5) over 10-months, independent of established risk factors and cardiac troponins, findings in contrast with our results [27,29,30]. The gene discussed is FABP3; the disease is hydrops fetalis.